Jae Park on Clinical Trials for CAR T-Cell Activation Therapy
Jae Park, MD, hematologist-oncologist, Memorial Sloan Kettering Cancer Center, talks about CAR T-cell activation therapy, which is currently in clinical trials for patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma.
Jae Park, MD, hematologist-oncologist, Memorial Sloan Kettering Cancer Center, talks about CAR T-cell activation therapy, which is currently in clinical trials for patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma.
Park says the trials show an 80% success rate for patients with ALL using the CAR T activation, and despite his hopes that it will eventually become a frontline therapy, not all patients are currently eligible for the trial.
Patients with ALL, CLL, or non-Hodgkin lymphoma who want to participate must have received at least one other therapy, such as a bone marrow transplant or chemotherapy, that has not worked.
Oncology Nurses Provide Patients an Avenue to Supportive Care
November 12th 2019Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that isn't the reality of what id can do for patients. And oncology nurses can help guide patients to the right supportive care for them.
Hyman B. Muss Discusses the Importance of Nurses in Treating Pregnant Women With Breast Cancer
March 23rd 2016Hyman B. Muss, MD, professor of medicine at the University of North Carolina School of Medicine, discusses the vital roles that nurses play when it comes to treating pregnant women with breast cancer.
